Systemic lupus erythematosus induced by interferon β1 therapy in a patient with multiple sclerosis

Bahri, D; Khiari, Hela Mrabet; Essouri, Asma; Laadhar, Lilia; Zarâa, I.; Mrabet, A.; Meddeb, N.; Sellami, Slaheddine

doi:10.1111/j.1472-8206.2011.00929.x

Cited by 16 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 21 However, few case reports have shown the development of SLE in patients with MS treated with INF. 22 – 24 This contrasts with what happened in our patient, since the symptoms of SLE were present when the medication was withdrawn and worsened despite receiving treatment with hydroxychloroquine. We believe that previous infection with the dengue virus could have triggered the expression of type I INF and the subsequent development of SLE as demonstrated in studies in which SLE developed in individuals who were exposed to live virus vaccines.…”

Section: Discussioncontrasting

confidence: 97%

Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review

Sánchez¹,

Castillo²,

González³

et al. 2018

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

Multiple sclerosis (MS) and systemic lupus erythematous (SLE) are autoimmune diseases, the coexistence of which is uncommon in patients. Owing to the rarity of this condition, the distinction between MS and SLE is a diagnostic challenge for neurologists. We present a case report in which MS and SLE were present in the same patient. There are few case reports in the world on the association between MS and SLE. The following case report is the first of its kind in which both MS and SLE are present in a patient from a country with low prevalence of MS such as Ecuador.

show abstract

Section: Discussioncontrasting

confidence: 97%

Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review

Sánchez¹,

Castillo²,

González³

et al. 2018

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

show abstract

“…SLE is a multisystemic autoimmune disease that can manifest itself in numerous pathological outcomes affecting skin, joints, lung, kidney and the CNS 38 . Indeed, it was reported in the literature that demyelinating disease in SLE in particular has the propensity to be accidentally misdiagnosed as other CNS affecting diseases such as MS 39 , and a case report showed an induction of SLE by interferon beta-1 treatment of a MS patient 40 , thereby demonstrating the potential autoimmune-link between these two diseases. RA, JIA and ERA are joint-affecting autoimmune disorders and are, like SLE, underpinned by chronic inflammation 41 .…”

Section: Discussionmentioning

confidence: 99%

Integrative analysis of Multiple Sclerosis using a systems biology approach

Cervantes-Gracia

Husi

2018

Sci Rep

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammatory-demyelinating events in the central nervous system. Despite more than 40 years of MS research its aetiology remains unknown. This study aims to identify the most frequently reported and consistently regulated molecules in MS in order to generate molecular interaction networks and thereby leading to the identification of deregulated processes and pathways which could give an insight of the underlying molecular mechanisms of MS. Driven by an integrative systems biology approach, gene-expression profiling datasets were combined and stratified into “Non-treated” and “Treated” groups and additionally compared to other disease patterns. Molecular identifiers from dataset comparisons were matched to our Multiple Sclerosis database (MuScle; www.padb.org/muscle). From 5079 statistically significant molecules, correlation analysis within groups identified a panel of 16 high-confidence genes unique to the naïve MS phenotype, whereas the “Treated” group reflected a common pattern associated with autoimmune disease. Pathway and gene-ontology clustering identified the Interferon gamma signalling pathway as the most relevant amongst all significant molecules, and viral infections as the most likely cause of all down-stream events observed. This hypothesis-free approach revealed the most significant molecular events amongst different MS phenotypes which can be used for further detailed studies.

show abstract

“…Nonetheless, case studies reporting drug related (mainly due to IFN-b) autoimmune rheumatic diseases (and in particular SLE) led several authors to conclude that unmasking of underlying autoimmune rheumatic disease cannot be taken lightly over the course of MS [26][27][28][29][30]. The same point has been raised very recently for AIH and other AiLDs diagnosed in patients with MS [9].…”

Section: Resultsmentioning

confidence: 99%

A comprehensive analysis of antigen-specific autoimmune liver disease related autoantibodies in patients with multiple sclerosis

Tsouris

Liaskos

Dardiotis

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction : Abnormal liver function tests are frequently seen in patients with multiple sclerosis (MS) and their origin at times is attributed to the possible co-occurrence or the de novo induction of autoimmune liver diseases (AILDAiLD), namely autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). Aim: To assess the presence of AILD-related autoantibodies in a well-defined cohort of MS patients. Material and Methods : 133 MS (93 female) patients (mean age 42.7±11.9SD years, mean duration of disease 11.2 ±7.2 years were studied. Eighty age and sex-matched healthy individuals were tested as normal controls (NCs). Autoantibody testing was performed by indirect immunofluorescence (IF) using triple tissue and HEp-2, a multiparametric line immunoassay detecting anti-LKM1(anti-CYP2D6), anti-LC1(anti-FTCD), soluble liver antigen/liver-pancreas(anti-SLA/LP), AMA-M2, and (AMA-M2-3E), PBC-specific ANA (anti-gp210, anti-sp100 and anti-PML), and ELISA for anti-F-actin SMA and anti-dsDNA antibodies. Results : The prevalence of at least one AILD-related autoabs was more frequent in MS patients compared to NCs (22.3% vs 7.25% p=0.0045). AIH-1 related anti-F-actin antibodies were present in 21 (15.8%), at relatively low titres (all but three of the SMA-VG pattern by IF); anti-dsDNA in 3 (2.3%), and anti-SLA/LP in none; AIH-2 anti-LKM1 autoantibodies in 1 (0.8 %, negative by IF), and anti-LC1 in none. PBC-specific AMA-M2 in 2 (1.5%), but negative for AMA-M2-3E and IF) and PBC-specific ANA anti-PML in 6 (4.5%), anti-sp100 in 1 (0.8 %) and anti-gp210 in 1 (0.8 %). Amongst the 30 MS patients with at least one autoab positivity, only 4 (3%) had overt AILD (2 AIH-1 and 2 PBC). Conclusions : Despite the relatively frequent presence of liver autoantibodies, tested either by IF or monospecific assays, overt disease is rather infrequent discouraging autoantibody screening strategies of MS patients in the absence of clinical suspicion.

show abstract

Systemic lupus erythematosus induced by interferon β1 therapy in a patient with multiple sclerosis

Cited by 16 publications

References 8 publications

Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review

Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review

Integrative analysis of Multiple Sclerosis using a systems biology approach

A comprehensive analysis of antigen-specific autoimmune liver disease related autoantibodies in patients with multiple sclerosis

Contact Info

Product

Resources

About